We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Renal failure
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Dialysis patients often have higher levels of phosphate compared with people with healthy kidneys. Research suggests that higher phosphate levels may increase the risk of heart disease and death. The current treatment guidelines suggest that high phosphate levels should be reduced towards the normal level. But evidence for these guidelines needs to be improved. Doctors don’t know if lowering blood phosphate towards a normal level is always a good option for patients receiving dialysis.
Phosphate levels can be reduced by diet, dialysis and medication. Medications used to reduce phosphate are called phosphate binders. Phosphate binder use increases the number of pills taken by dialysis patients. These medications can also cause side effects.
The study will examine whether reducing phosphate levels in dialysis patients will improve:
Life expectancy
Heart health
How patients feel or function.
It is a randomised study. This means that if a patient decides to take part in the study, they will be “assigned” to either a higher or lower blood phosphate target by chance. It is up to the patient's doctor to recommend changes to their diet, adjust their dialysis prescription or prescribe phosphate binders to meet this target.
The study will include 3,600 patients from Australia, New Zealand, Canada and the UK. We expect about 2000 to be enrolled from up to 60 centres across the UK.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Drug;Education or Self-Management;Dietary;Management of Care;Active Monitoring;
You can take part if:
You may not be able to take part if:
1. Elective kidney transplantation scheduled within the next 6 months, 2. Concomitant major illness / comorbidity likely to result in death in the next 6 months in the view of the treating physician 3. Participation in an interventional study that is likely to affect serum phosphate concentration.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 50088
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
